Log In


All News

Sort By News Date & Time Sort Descending Order News Source News Title

  Refine Search  
Date Range
News Type

19/09/2017 7:31PM

CHMP positive opinion to include RE-CIRCUIT® data for atrial fibrillation patients undergoing catheter ablation in Pradaxa® Summary of Product Characteristics

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for an update to the European Summary of Product Characteristics (SmPC) of Pradaxa® ...

28/08/2017 1:15PM

Pradaxa® (dabigatran etexilate) dual therapy showed lower rates of major bleeding versus triple therapy with warfarin in atrial fibrillation patients undergoing stent placement

The RE-DUAL PCI™ trial explored anticoagulation with Pradaxa® (dabigatran etexilate) dual therapy without aspirin in non-valvular atrial fibrillation (AF) patients following percutaneous coronary intervention ...

16/11/2017 12:35PM

Key sub-analyses of RE-DUAL PCI™ showed large reductions in the incidence of bleeding complications if Pradaxa® (dabigatran etexilate) dual therapy was used instead of warfarin triple therapy

Boehringer Ingelheim has shared sub-analyses from the RE-DUAL PCI™ clinical trial at the AHA Scientific Sessions 2017 in Anaheim, California. RE-DUAL PCI™ investigated different treatment approaches in ...

03/03/2015 2:39PM

Boehringer Ingelheim submits applications for approval of idarucizumab*, specific reversal agent to dabigatran etexilate (Pradaxa®), to EMA, FDA and Health Canada

For Non-US/Non-UK/Non-Canadian Media   Boehringer Ingelheim today announces that idarucizumab has been submitted for approval of marketing authorisation to the European Medicines Agency (EMA), U.S. Food and ...

17/03/2015 10:50AM

Many Atrial Fibrillation patients at high risk of stroke fail to receive guideline-recommended oral anticoagulant treatment

For Non-US/Non-UK/Non-Canadian Media   Boehringer Ingelheim today announces two analyses from the GLORIA™-AF Registry Program examining the use of anticoagulant treatments for stroke prevention in ...

21/03/2015 11:31AM

Boehringer Ingelheim’s investigational biologic cleared skin better than ustekinumab in head-to-head Phase II psoriasis study

For non-UK/non-Canadian media only   For the first time, Boehringer Ingelheim announced Phase II data from its investigational compound BI 655066*. Nearly double the percentage of patients with ...

01/04/2015 6:21PM

Type 2 Diabetes: CHMP Recommends Empagliflozin/Metformin Hydrochloride for Approval in the European Union

For media outside the US, the UK and Canada only   Boehringer Ingelheim (BI) and Eli Lilly and Company (Lilly) today announced they have received a positive opinion from the Committee for Medicinal Products for ...

18/04/2015 10:05AM

New international survey of lung cancer oncologists highlights underutilization of personalized treatments

For media outside the US, the UK and Canada only   Results from a new global survey of lung cancer oncologists have shown that despite 81% of newly diagnosed advanced non-small cell lung cancer (NSCLC) patients ...